0R15 8539.0 2.1534% 0R1E 8600.0 3.3654% 0M69 None None% 0R2V 190.25 -0.1312% 0QYR 1345.5 2.0871% 0QYP 424.0 0.5931% 0LCV 146.6464 -1.3147% 0RUK None None% 0RYA 1631.0 -0.6094% 0RIH 171.3 0.9131% 0RIH 174.9 2.1016% 0R1O 186.0 9820.0% 0R1O None None% 0QFP None None% 0M2Z 298.3 -0.6495% 0VSO None None% 0R1I None None% 0QZI 474.5 0.6363% 0QZ0 220.0 0.0% 0NZF None None%
Last update at 2024-05-16T15:41:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 2501.00M | -265.00000M | 3916.00M | 1548.00M | 1993.00M |
| Minority interest | -5.00000M | -3.00000M | 16.00M | 1469.00M | 1576.00M |
| Net income | 3288.00M | 112.00M | 3196.00M | 1335.00M | 2155.00M |
| Selling general administrative | 18955.00M | 95.00M | 11693.00M | 12021.00M | 10362.00M |
| Selling and marketing expenses | 18955.00M | 15680.00M | 11693.00M | 11848.00M | 10362.00M |
| Gross profit | 31960.00M | 24980.00M | 21318.00M | 19463.00M | 17154.00M |
| Reconciled depreciation | 5480.00M | 6530.00M | 3149.00M | 3762.00M | 3753.00M |
| Ebit | 3757.00M | 1056.00M | 5162.00M | 2924.00M | 3464.00M |
| Ebitda | 9327.00M | 7565.00M | 8371.00M | 7016.00M | 7217.00M |
| Depreciation and amortization | 5570.00M | 6509.00M | 3209.00M | 4092.00M | 3753.00M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 3757.00M | 1056.00M | 5162.00M | 2924.00M | 1510.00M |
| Other operating expenses | 40594.00M | 36361.00M | 21455.00M | 21186.00M | 20580.00M |
| Interest expense | 1346.00M | 1300.00M | 1306.00M | 1432.00M | 1366.00M |
| Tax provision | -792.00000M | -380.00000M | 772.00M | 321.00M | -57.00000M |
| Interest income | 95.00M | 43.00M | 87.00M | 145.00M | 132.00M |
| Net interest income | -1251.00000M | -1257.00000M | -1219.00000M | -1237.00000M | -1228.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -792.00000M | -380.00000M | 772.00M | 321.00M | -57.00000M |
| Total revenue | 44351.00M | 37417.00M | 26617.00M | 24384.00M | 22090.00M |
| Total operating expenses | 28203.00M | 23924.00M | 16156.00M | 16265.00M | 15644.00M |
| Cost of revenue | 12391.00M | 12437.00M | 5299.00M | 4921.00M | 4936.00M |
| Total other income expense net | -1256.00000M | -1321.00000M | -1246.00000M | -1376.00000M | 483.00M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 3293.00M | 115.00M | 3144.00M | 1227.00M | 2050.00M |
| Net income applicable to common shares | 3288.00M | 112.00M | 3196.00M | 1335.00M | 2155.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 96483.00M | 105363.00M | 66729.00M | 61377.00M | 60651.00M |
| Intangible assets | 39307.00M | 42387.00M | 20947.00M | 20833.00M | 21959.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 11489.00M | 105.00M | 7570.00M | 6190.00M | 7147.00M |
| Total liab | 59425.00M | 66076.00M | 51091.00M | 46781.00M | 46607.00M |
| Total stockholder equity | 37037.00M | 39268.00M | 15622.00M | 13127.00M | 12468.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1711.00M | 1763.00M | 2136.00M | 2120.00M | 11450.00M |
| Common stock | 387.00M | 387.00M | 328.00M | 328.00M | 317.00M |
| Capital stock | 387.00M | 387.00M | 328.00M | 328.00M | 317.00M |
| Retained earnings | -574.00000M | 1710.00M | 5299.00M | 2812.00M | 5683.00M |
| Other liab | 8499.00M | 13011.00M | 10491.00M | 10283.00M | 11114.00M |
| Good will | 19820.00M | 19997.00M | 11845.00M | 11668.00M | 11707.00M |
| Other assets | 4172.00M | 5327.00M | 4284.00M | 3466.00M | 2995.00M |
| Cash | 6166.00M | 6329.00M | 7832.00M | 5369.00M | 4745.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 26293.00M | 22594.00M | 20307.00M | 18117.00M | 16292.00M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 23066.00M | 24452.00M | 12548.00M | 12858.00M | 14368.00M |
| Short term debt | 5542.00M | 1893.00M | 2386.00M | 2010.00M | 1754.00M |
| Short long term debt | 5314.00M | 1660.00M | 2194.00M | 1822.00M | 1754.00M |
| Short long term debt total | 29232.00M | 30781.00M | 20380.00M | 18227.00M | 19113.00M |
| Other stockholder equity | 37224.00M | 37171.00M | 9995.00M | 9987.00M | 6468.00M |
| Property plant equipment | 9449.00M | 10171.00M | 8917.00M | 8335.00M | 7421.00M |
| Total current assets | 22593.00M | 26244.00M | 19544.00M | 15563.00M | 15591.00M |
| Long term investments | - | - | - | 1512.00M | 978.00M |
| Net tangible assets | -22090.00000M | -23116.00000M | -17170.00000M | -19374.00000M | -21198.00000M |
| Short term investments | 239.00M | 69.00M | 160.00M | 849.00M | 809.00M |
| Net receivables | 10521.00M | 10758.00M | 5651.00M | 5181.00M | 4837.00M |
| Long term debt | 22965.00M | 28134.00M | 17505.00M | 15730.00M | 17359.00M |
| Inventory | 4699.00M | 8983.00M | 4024.00M | 3193.00M | 2890.00M |
| Accounts payable | 19040.00M | 18938.00M | 15785.00M | 13987.00M | 1720.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -8193.00000M | -7517.00000M | -7218.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 328.00M | 328.00M | 317.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1148.00M | 1066.00M | 1051.00M | 1650.00M | 1481.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 73890.00M | 79119.00M | 47185.00M | 45814.00M | 45060.00M |
| Capital lease obligations | 953.00M | 987.00M | 681.00M | 675.00M | 0.00000M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2960.00000M | 605.00M | 1999.00M | 125.00M | 140.00M |
| Change to liabilities | 1165.00M | 1405.00M | 1721.00M | 868.00M | -103.00000M |
| Total cashflows from investing activities | -2960.00000M | -11058.00000M | -285.00000M | -657.00000M | 963.00M |
| Net borrowings | -1441.00000M | 7654.00M | 1440.00M | -1702.00000M | 1473.00M |
| Total cash from financing activities | -6823.00000M | 3649.00M | -2203.00000M | -1765.00000M | -2044.00000M |
| Change to operating activities | - | 2021.00M | 361.00M | 361.00M | 361.00M |
| Net income | 2501.00M | -265.00000M | 3916.00M | 1548.00M | 2155.00M |
| Change in cash | -55.00000M | -1508.00000M | 2323.00M | 552.00M | 1499.00M |
| Begin period cash flow | 6038.00M | 7546.00M | 5223.00M | 4671.00M | 3172.00M |
| End period cash flow | 5983.00M | 6038.00M | 7546.00M | 5223.00M | 4671.00M |
| Total cash from operating activities | 9808.00M | 5963.00M | 4799.00M | 2969.00M | 2618.00M |
| Issuance of capital stock | 29.00M | 29.00M | 30.00M | 3525.00M | 34.00M |
| Depreciation | 5480.00M | 6530.00M | 3149.00M | 3762.00M | 3753.00M |
| Other cashflows from investing activities | 60.00M | 54.00M | 87.00M | 274.00M | 193.00M |
| Dividends paid | 4364.00M | 3856.00M | 3572.00M | 3592.00M | 3484.00M |
| Change to inventory | 3941.00M | 1577.00M | -621.00000M | -316.00000M | -13.00000M |
| Change to account receivables | -1349.00000M | -961.00000M | -739.00000M | -898.00000M | -523.00000M |
| Sale purchase of stock | -920.00000M | 12413.00M | 3049.00M | 314.00M | 34.00M |
| Other cashflows from financing activities | -297.00000M | -178.00000M | -101.00000M | 4.00M | 2904.00M |
| Change to netincome | -2491.00000M | -615.00000M | -1650.00000M | -816.00000M | -1709.00000M |
| Capital expenditures | 2571.00M | 2200.00M | 2606.00M | 2460.00M | 1371.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 3757.00M | 2021.00M | 361.00M | -346.00000M | -639.00000M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -1930.00000M | -2323.00000M | -2627.00000M | -1995.00000M | -2651.00000M |
| Free cash flow | 7237.00M | 3763.00M | 2193.00M | 509.00M | 1247.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AZN AstraZeneca PLC |
-6.0 0.05% | 12166.00 | 34.90 | 15.70 | 3.61 | 5.45 | 3.98 | 13.14 |
| GSK GlaxoSmithKline PLC |
-29.0 1.60% | 1783.50 | 9.79 | 9.19 | 2.01 | 4.53 | 2.48 | 7.65 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
| Name | Title | Year Born |
|---|---|---|
| Mr. Pascal Soriot D.V.M., M.B.A. | CEO & Exec. Director | 1959 |
| Dr. Aradhana Sarin M.D. | CFO & Exec. Director | 1975 |
| Mr. Marc Dunoyer | CEO of Alexion & Chief Strategy Officer | 1952 |
| Ms. Pam P. Cheng | EVP of Operations & Information Technology and Member of External Sustainability Advisory Board | 1971 |
| Mr. Chris Sheldon | Head of Investor Relations | NA |
| Mr. Jeffrey Pott | Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board | NA |
| Ms. Katarina Ageborg | EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board | NA |
| Gonzalo Vina | Head of Global Media Relations | NA |
| Dr. Menelas Pangalos Ph.D. | EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board | 1967 |
| Dr. Ruud Dobber Ph.D. | Exec. Vice-Pres of BioPharmaceuticals Bus. Unit | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...